The scatter plots of EZH2 expression and these immune infiltration cells in GBM, LUSC, TGCT, and sarcoma (SARC) further confirmed that EZH2 might suppress antitumor immunity by reducing the antitumor immune cell infiltration, leading to unfavorable prognosis in patients with various cancers (Figure 9C). Here, EZH2 is linked to sarcoma.